AirSculpt Technologies, Inc. (AIRS) - Q1 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2025. AirSculpt Technologies, Inc. operates as a practice management service organization providing specialty, minimally invasive liposuction procedures through a network of 32 centers across 20 states, Canada, and the United Kingdom. The company is classified as a smaller reporting company and an emerging growth company.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Revenue | $39.4 million | $47.6 million |
| Net Loss | $(2.8) million | $6.0 million (Income) |
| Operating Loss | $(1.6) million | $11.0 million (Income) |
| Adjusted EBITDA | $3.8 million | $7.3 million |
| Operating Cash Flow | $0.9 million | $3.4 million |
| Cash and Equivalents | $5.6 million | $11.0 million |
| Total Debt (Net) | $68.5 million | $69.7 million |
| Working Capital | $(11.5) million | $(11.5) million |
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased 17.3% year-over-year, driven by a 17.9% drop in total cases performed (3,076 vs. 3,746). Same-center case volume declined 24.3%.
- Profitability Shift: The company reported a net loss of $2.8 million compared to net income of $6.0 million in Q1 2024. This reversal is partly due to the absence of a $10.4 million stock compensation expense reversal recorded in Q1 2024.
- Expense Increases: Selling, general, and administrative (SG&A) expenses rose 38.2% to $21.8 million, primarily due to the normalization of stock compensation expenses and increased corporate SG&A. Cost of service decreased 11.6% in line with lower case volume.
- Liquidity Reduction: Cash and cash equivalents decreased by $2.7 million to $5.6 million, reflecting a net cash outflow from operations and investing activities.
Guidance, Outlook, and Risks
Management Commentary & Strategy: Management announced a strategic initiative to stabilize revenue growth, including optimizing marketing spend, enhancing the sales process, and launching expanded consumer financing. A cost reduction program targeting $3.0 million in annual overhead savings has been implemented, and new center openings have been paused.
Debt Covenant Amendment: On March 12, 2025, the company amended its Credit Agreement. Key changes include:
- Relaxed Fixed Charge Coverage and Leverage Ratio covenants for Q1 and Q2 2025.
- Requirement to maintain minimum liquidity of $3.0 million (March), $5.0 million (April), and $7.5 million (May and thereafter).
- Increased interest rate margins effective July 1, 2025, based on leverage ratios.
- A $10.0 million limited guarantee provided by the private equity sponsor (Vesey Street Capital Partners), callable if the company fails to prepay $10.0 million of the term loan by June 15, 2025.
Risks: The company faces risks related to the broader aesthetics industry slowdown, competition from weight-loss drugs, and the ability to raise capital. The revolving credit facility is fully drawn ($5.0 million), leaving no immediate borrowing capacity without covenant compliance.
Investor Verification Checklist
- Liquidity Covenant Compliance: Verify if the company meets the escalating minimum liquidity requirements ($5M by April 30, $7.5M by May 31) to avoid default.
- Debt Prepayment Obligation: Confirm the company's ability to prepay $10.0 million of the term loan by June 15, 2025, to prevent the sponsor's limited guarantee from being called.
- Revenue Stabilization: Monitor upcoming quarters for signs of stabilization in same-center case volumes and revenue per case.
- Capital Raising: Track the utilization of the new At-The-Market (ATM) offering program, which has generated minimal proceeds ($13k) to date.
- Cost Reduction Execution: Assess whether the targeted $3.0 million in annual cost savings is being realized in subsequent quarters.